The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.

Saved in:
Bibliographic Details
Title: The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.
Authors: Su A; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Ling F; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Vaganay C; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Sodaro G; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Benaksas C; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Dal Bello R; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Forget A; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Pardieu B; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Lin KH; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina., Rutter JC; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina., Bassil CF; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina., Fortin G; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Pasanisi J; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Antony-Debré I; INSERM UMR 1287, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France., Alexe G; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.; The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts., Benoist JF; AP-HP, Biochemistry-Hormonology Department, Robert Debré Hospital, Paris, France., Pruvost A; Paris-Saclay University, CEA, INRAE, Département Médicaments et Technologies pour la santé, SPI, Gif-sur-Yvette, France., Pikman Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Cancer Biology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Qi J; The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Department of Cancer Biology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Schlageter MH; AP-HP, Cellular Biology Department, St Louis Hospital, Paris, France.; INSERM U 1131, IRSL, St Louis Hospital, University of Paris, Paris, France., Micol JB; INSERM UMR 1287, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.; Department of Hematology, Gustave Roussy Institute, Villejuif, France., Roti G; University of Parma, Department of Medicine and Surgery, Parma, Italy., Cluzeau T; Department of Hematology, Centre Hospitalier Universitaire, Nice, France., Dombret H; LTL, IRSL, St Louis Hospital, Paris, France., Preudhomme C; Laboratory of Hematology, CHU Lille, Lille, France., Fenouille N; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France., Benajiba L; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.; AP-HP, Hematology Department, St Louis Hospital, Paris, France., Golan HM; Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.; The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts., Lobry C; INSERM UMR 1287, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France., Wood KC; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina., Itzykson R; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France. alexandre.puissant@inserm.fr raphael.itzykson@aphp.fr., Puissant A; INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France. alexandre.puissant@inserm.fr raphael.itzykson@aphp.fr.
Source: Cancer discovery [Cancer Discov] 2020 Dec; Vol. 10 (12), pp. 1894-1911. Date of Electronic Publication: 2020 Aug 21.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-19-0970